TN2013000321A1 - C-17 and c-3 modified triterpenoids with hiv maturation inhibitory activity - Google Patents

C-17 and c-3 modified triterpenoids with hiv maturation inhibitory activity

Info

Publication number
TN2013000321A1
TN2013000321A1 TNP2013000321A TN2013000321A TN2013000321A1 TN 2013000321 A1 TN2013000321 A1 TN 2013000321A1 TN P2013000321 A TNP2013000321 A TN P2013000321A TN 2013000321 A TN2013000321 A TN 2013000321A TN 2013000321 A1 TN2013000321 A1 TN 2013000321A1
Authority
TN
Tunisia
Prior art keywords
inhibitory activity
hiv maturation
compounds
modified triterpenoids
hiv
Prior art date
Application number
TNP2013000321A
Other languages
English (en)
Inventor
Alicia Regueiro-Ren
Zheng Liu
Jacob Swidorski
Ny Sin
Brian Lee Venables
Sing-Yuen Sit
Yan Chen
Jie Chen
Nicholas A Meanwell
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of TN2013000321A1 publication Critical patent/TN2013000321A1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J63/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J63/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008Expansion of ring D by one atom, e.g. D homo steroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TNP2013000321A 2011-01-31 2013-07-26 C-17 and c-3 modified triterpenoids with hiv maturation inhibitory activity TN2013000321A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161437893P 2011-01-31 2011-01-31
PCT/US2012/022852 WO2012106190A1 (fr) 2011-01-31 2012-01-27 Triterpénoïdes modifiés en c-17 et c-3 présentant une activité inhibitrice de la maturation du vih

Publications (1)

Publication Number Publication Date
TN2013000321A1 true TN2013000321A1 (en) 2015-01-20

Family

ID=45567147

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2013000321A TN2013000321A1 (en) 2011-01-31 2013-07-26 C-17 and c-3 modified triterpenoids with hiv maturation inhibitory activity

Country Status (24)

Country Link
US (3) US8846647B2 (fr)
EP (1) EP2670765B1 (fr)
JP (1) JP6001560B2 (fr)
KR (1) KR101886467B1 (fr)
CN (1) CN103429607B (fr)
AR (1) AR085053A1 (fr)
AU (1) AU2012212509B2 (fr)
BR (1) BR112013019419A2 (fr)
CA (1) CA2826113C (fr)
CL (1) CL2013002185A1 (fr)
CO (1) CO6751275A2 (fr)
EA (1) EA022470B1 (fr)
ES (1) ES2653847T3 (fr)
IL (1) IL227678B (fr)
MA (1) MA34909B1 (fr)
MY (1) MY162186A (fr)
PE (1) PE20141152A1 (fr)
PT (1) PT2670765T (fr)
SG (1) SG192144A1 (fr)
TN (1) TN2013000321A1 (fr)
TW (1) TWI628188B (fr)
UY (1) UY33886A (fr)
WO (1) WO2012106190A1 (fr)
ZA (1) ZA201306546B (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102164941B (zh) 2008-04-18 2015-05-27 里亚塔医药公司 抗氧化剂炎症调节剂:具有饱和c环的齐墩果酸衍生物
BRPI0911422B8 (pt) 2008-04-18 2021-05-25 Reata Pharmaceuticals Inc compostos moduladores inflamatórios antioxidantes, composição farmacêutica e usos dos mesmos
MX2010011435A (es) 2008-04-18 2011-01-25 Reata Pharmaceuticals Inc Compuestos que incluyen un nucleo farmaceutico antiinflamatorio y sus metodos de uso.
CA2721838C (fr) 2008-04-18 2017-05-23 Reata Pharmaceuticals, Inc. Modulateurs d'inflammation antioxydants: derives d'acide oleanolique presentant une modification du groupe amino et d'autres modifications en c-17
US8513436B2 (en) 2010-12-17 2013-08-20 Reata Pharmaceuticals, Inc. Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators
SI2670764T1 (sl) * 2011-01-31 2016-03-31 Bristol-Myers Squibb Company C-28 amini derivatov c-3 modificirane betulinske kisline inhibitorjev zorenja hiv
MX348862B (es) 2011-03-11 2017-07-03 Reata Pharmaceuticals Inc Derivados c4-monometil triterpenoides y sus metodos de uso.
CN103814042B (zh) 2011-09-21 2015-08-19 百时美施贵宝公司 具有抗病毒活性的桦木酸衍生物
US8906889B2 (en) * 2012-02-15 2014-12-09 Bristol-Myers Squibb Company C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity
WO2013163344A1 (fr) 2012-04-27 2013-10-31 Reata Pharmaceuticals, Inc. Dérivés 2,2-difluoropropionamide de bardoxolone méthyle, leurs formes polymorphes et leurs procédés d'utilisation
US8889854B2 (en) * 2012-05-07 2014-11-18 Bristol-Myers Squibb Company C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity
US9556222B2 (en) 2012-06-15 2017-01-31 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
CN107163038B (zh) * 2012-08-15 2020-07-28 葛兰素集团有限公司 化学方法
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
US9278912B2 (en) 2012-09-10 2016-03-08 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
DK2892912T3 (da) 2012-09-10 2019-06-24 Reata Pharmaceuticals Inc C17-alkandiyl og alkenediylderivater af oleanolsyre og fremgangsmåder til anvendelse deraf
AU2014215468B2 (en) * 2013-02-06 2017-05-18 VIIV Healthcare UK (No.5) Limited C-19 modified triterpenoids with HIV maturation inhibitory activity
JP6186012B2 (ja) 2013-02-25 2017-08-23 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company C−3アルキルおよびアルケニル修飾ベツリン酸誘導体
EP3750910A1 (fr) 2014-04-11 2020-12-16 VIIV Healthcare UK(No.4) Limited Triterpénoïdes présentant une activité d'inhibition de la maturation du vih
US9920090B2 (en) 2014-06-19 2018-03-20 VIIV Healthcare UK (No.5) Limited Betulinic acid derivatives with HIV maturation inhibitory activity
WO2016077569A1 (fr) * 2014-11-14 2016-05-19 Bristol-Myers Squibb Company Analogues de l'acide bétulinique substitués par aryle en c17
EP3218387A1 (fr) 2014-11-14 2017-09-20 VIIV Healthcare UK (No.5) Limited Dérivés d'oxolupène
AU2016248235A1 (en) 2015-04-14 2017-10-19 Viiv Healthcare Uk (No 4) Limited Crystalline forms of modified triterpenoid hydrochloride salts with HIV maturation inhibitor activity
US20180194799A1 (en) 2015-07-28 2018-07-12 Glaxosmithkline Intellectual Property (No.2) Limited Betuin derivatives for preventing or treating hiv infections
KR20180028534A (ko) 2015-07-28 2018-03-16 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 Hiv 감염을 예방하거나 치료하기 위한 베투인 유도체
WO2017025901A1 (fr) * 2015-08-11 2017-02-16 Hetero Research Foundation Nouveaux analogues de c28 à modifications en c3 de dérivés triterpéniques à utiliser en tant qu'inhibiteurs du vih
KR20180061251A (ko) 2015-09-23 2018-06-07 리아타 파마슈티컬즈, 아이엔씨. Il-17의 저해를 위한 c4-변형된 올레아놀산 유도체 및 다른 용도
CA2998828A1 (fr) 2015-09-24 2017-03-30 Glaxosmithkline Intellectual Property (No.2) Limited Composes a activite inhibitrice de la maturation du vih
BR112018010163A2 (pt) 2015-11-20 2018-11-21 Viiv Healthcare Uk No 4 Ltd formulação, e, método para tratamento de infecção por hiv
JP2019502728A (ja) 2016-01-20 2019-01-31 グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited Hiv成熟阻害活性を有するルパンのアミン誘導体
AR107512A1 (es) 2016-02-04 2018-05-09 VIIV HEALTHCARE UK Nº 5 LTD Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
US20190135857A1 (en) * 2016-06-30 2019-05-09 Viiv Healthcare Uk (No. 5) Limited Triterpenoid inhibitors of human immunodeficiency virus replication
WO2018044822A1 (fr) * 2016-08-31 2018-03-08 Viiv Healthcare Company Combinaisons, utilisations et traitements correspondants
EP3661945B1 (fr) 2017-08-04 2024-04-03 Ardelyx, Inc. Dérivés d'acide glycyrrhétinique de traitement de l'hyperkaliémie
JP6926939B2 (ja) * 2017-10-23 2021-08-25 東京エレクトロン株式会社 半導体装置の製造方法
JP6977474B2 (ja) * 2017-10-23 2021-12-08 東京エレクトロン株式会社 半導体装置の製造方法
JP7436385B2 (ja) 2018-04-24 2024-02-21 ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド Hiv成熟阻害活性を有する化合物
PL237998B1 (pl) 2018-05-28 2021-06-28 Narodowy Inst Lekow Fosfonowe pochodne kwasu 3-karboksyacylobetulinowego, sposób ich otrzymywania oraz ich zastosowanie
AU2020218255A1 (en) 2019-02-07 2021-09-09 Ardelyx, Inc. Glycyrrhetinic acid derivatives for use in treating hyperkalemia
CA3129743A1 (fr) 2019-02-11 2020-08-20 Hetero Labs Limited Nouveaux derives de triterpene en tant qu'inhibiteurs du vih
GB2598300A (en) * 2020-08-21 2022-03-02 Univ Durham Cross-linking method and applications in bioconjugation

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5962527A (en) 1995-03-21 1999-10-05 The Board Of Trustees Of The University Of Illinois Method and composition for treating cancers
US5869535A (en) 1995-03-21 1999-02-09 The Board Of Trustees Of The University Of Illinois Method and composition for selectively inhibiting melanoma
US5679828A (en) 1995-06-05 1997-10-21 Biotech Research Labs, Inc. Betulinic acid and dihydrobetulinic acid derivatives and uses therefor
US20020137755A1 (en) 2000-12-04 2002-09-26 Bilodeau Mark T. Tyrosine kinase inhibitors
US20040110785A1 (en) 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US7365221B2 (en) 2002-09-26 2008-04-29 Panacos Pharmaceuticals, Inc. Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
WO2004089357A2 (fr) 2003-04-02 2004-10-21 Regents Of The University Of Minnesota Preparation antifongique a base de triterpene et d'huile essentielle
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
US20050239748A1 (en) 2004-03-17 2005-10-27 Panacos Pharmaceuticals, Inc. Pharmaceutical salts of 3-O-(3',3'-dimethylsuccinyl) betulinic acid
TW200628161A (en) * 2004-11-12 2006-08-16 Panacos Pharmaceuticals Inc Novel betulin derivatives, preparation thereof and use thereof
US8067620B2 (en) 2005-05-04 2011-11-29 Medicines For Malaria Venture Mmv Dispiro 1,2,4-trioxolane antimalarials
WO2008127364A2 (fr) 2006-10-13 2008-10-23 Myriad Genetics, Inc. Composés antiviraux et utilisation de ceux-ci
US20090105203A1 (en) 2006-10-16 2009-04-23 Myriad Genetics, Incorporated Compounds for treating viral infections
WO2009100532A1 (fr) 2008-02-14 2009-08-20 Virochem Pharma Inc. Nouveaux dérivés de 17ss-lupane
US9067966B2 (en) 2009-07-14 2015-06-30 Hetero Research Foundation, Hetero Drugs Ltd. Lupeol-type triterpene derivatives as antivirals
CN102985438B (zh) * 2010-06-04 2016-05-18 百时美施贵宝公司 作为hiv成熟抑制剂的经修饰c-3桦木酸衍生物的c-28酰胺
CN103038245B (zh) * 2010-06-04 2015-03-25 百时美施贵宝公司 作为hiv成熟抑制剂的c-3经修饰的桦木酸衍生物

Also Published As

Publication number Publication date
MA34909B1 (fr) 2014-02-01
PE20141152A1 (es) 2014-09-22
US8846647B2 (en) 2014-09-30
IL227678A0 (en) 2013-09-30
NZ614871A (en) 2014-06-27
EA022470B1 (ru) 2016-01-29
IL227678B (en) 2018-04-30
CA2826113A1 (fr) 2012-08-09
ZA201306546B (en) 2015-03-25
KR101886467B1 (ko) 2018-08-07
US20130035318A1 (en) 2013-02-07
CN103429607B (zh) 2016-02-17
US20140343000A1 (en) 2014-11-20
BR112013019419A2 (pt) 2019-12-03
CL2013002185A1 (es) 2013-12-27
EP2670765A1 (fr) 2013-12-11
PT2670765T (pt) 2018-01-08
AU2012212509B2 (en) 2016-01-21
SG192144A1 (en) 2013-08-30
JP6001560B2 (ja) 2016-10-05
KR20140016279A (ko) 2014-02-07
AR085053A1 (es) 2013-08-07
TW201309717A (zh) 2013-03-01
EP2670765B1 (fr) 2017-10-18
AU2012212509A1 (en) 2013-09-19
CA2826113C (fr) 2018-09-04
MY162186A (en) 2017-05-31
US20160151387A1 (en) 2016-06-02
CN103429607A (zh) 2013-12-04
JP2014503595A (ja) 2014-02-13
WO2012106190A1 (fr) 2012-08-09
TWI628188B (zh) 2018-07-01
EA201391127A1 (ru) 2013-12-30
CO6751275A2 (es) 2013-09-16
UY33886A (es) 2012-07-31
ES2653847T3 (es) 2018-02-09

Similar Documents

Publication Publication Date Title
TN2013000321A1 (en) C-17 and c-3 modified triterpenoids with hiv maturation inhibitory activity
MX2012013628A (es) Amidas c-28 de derivados del acido betulinico c-3 modificados como inhibidores de la maduracion del virus de inmunodeficiencia humana (vih).
MX2012013703A (es) Derivados de acido c-3-betulinico modificados como inhibidores de la maduracion del virus de inmunodeficiencia humana (vih).
MX2014013089A (es) Aminas biciclicas c-17 de triterpenoides con actividad inhibidora de la maduracion del virus de inmunodeficiencia humana (vih).
MX2015010354A (es) Derivados de acido betulinico modificados con aquilo c-3 y alquenilo utiles en el tratamiento de virus de inmunodeficiencia humana (vih).
MX2013008359A (es) Aminas de c-28 de derivados de acido betulinico modificado de c-3 como inhibidores de la maduracion del virus de inmunodeficiencia humana.
PH12014501816A1 (en) C-3 cycloalkenyl triterpenoids with hiv maturation inhibitory activity
MX2015010003A (es) Triterpenoides c-19 modificados, con actividad inhibidora de la maduracion del virus de inmunodeficiencia humana (vih).
AU2012253757A8 (en) Partially saturated tricyclic compounds and methods of making and using same
PH12015500274A1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
MX344238B (es) Compuestos de tetrazol y métodos para preparar y usar los mismos.
AU2012253759A8 (en) Tricyclic sulfonamide compounds and methods of making and using same
MX2014012695A (es) Derivados de isoindolona.
GEP20186838B (en) 5-phenoxy-3h-pyrimidin-4-one derivatives and their usage as hiv reverse transcriptase inhibitors
NZ720478A (en) Autotaxin inhibitor compounds
IN2014DN09434A (fr)
MX343688B (es) Compuestos tricíclicos de sulfonamida y pirazolo y métodos para su fabricación y uso.
IN2015DN01119A (fr)
MX2014002936A (es) Nuevos derivados de acido betulinico con actividad antiviral.
MX340574B (es) Imidazo pirazinas.
JOP20170029B1 (ar) C-3 وc-17 تراي تربينويد معدلة كمثبطات لـhiv-1
PH12015500282A1 (en) N-acylhydrazone derivatives for selective t cell inhibitor and anti-lymphoid malignancy drug
MX2013008536A (es) Triterpenoides c-17 y c-3 modificados con actividad inhibidora de la maduracion del virus de inmunodeficiencia humana.
PH12018501640A1 (en) C-3 and c-17 modified triterpenoids as hiv-1 inhibitors
NZ625516A (en) Derivatives of betulin